Are Randomized Controlled Trials Necessary to Establish the Value of Implementing Pharmacogenomics in the Clinic?
作者信息
Huddart Rachel, Sangkuhl Katrin, Whirl-Carrillo Michelle, Klein Teri E
机构信息
Department of Biomedical Data Science, Stanford University, Stanford, California, USA.
Department of Medicine, Stanford University, Stanford, California, USA.
出版信息
Clin Pharmacol Ther. 2019 Aug;106(2):284-286. doi: 10.1002/cpt.1420. Epub 2019 Apr 12.
Abstract
摘要
相似文献
1
Are Randomized Controlled Trials Necessary to Establish the Value of Implementing Pharmacogenomics in the Clinic?
Clin Pharmacol Ther. 2019 Aug;106(2):284-286. doi: 10.1002/cpt.1420. Epub 2019 Apr 12.
2
Interpreting and Implementing Clinical Pharmacogenetic Tests: Perspectives From Service Providers.
Clin Pharmacol Ther. 2019 Aug;106(2):298-301. doi: 10.1002/cpt.1494. Epub 2019 Jun 4.
3
Pharmacogenetics: Chasing Perfection.
Clin Pharmacol Ther. 2019 Aug;106(2):265-270. doi: 10.1002/cpt.1511.
4
Progress and Challenges in Pharmacogenomics.
Clin Pharmacol Ther. 2021 Sep;110(3):529-532. doi: 10.1002/cpt.2359.
5
Pharmacogenomics: Prescribing Precisely.
Med Clin North Am. 2019 Nov;103(6):977-990. doi: 10.1016/j.mcna.2019.07.002. Epub 2019 Aug 24.
6
Personalized Medicine and Adverse Drug Reactions: The Experience of An Italian Teaching Hospital.
Curr Pharm Biotechnol. 2017;18(3):274-281. doi: 10.2174/1389201018666170207124835.
7
Pharmacogenomics of adverse drug reactions: practical applications and perspectives.
Pharmacogenomics. 2009 Jun;10(6):961-9. doi: 10.2217/pgs.09.37.
8
Herbal Remedies: Throwing Off Phenotype Prediction-A Culprit for Pharmacogenomic-Guided Drug Therapy and Drug Safety.
Clin Pharmacol Ther. 2019 Aug;106(2):302-304. doi: 10.1002/cpt.1509. Epub 2019 Jun 27.
9
The IGNITE Pharmacogenetics Working Group: An Opportunity for Building Evidence with Pharmacogenetic Implementation in a Real-World Setting.
Clin Transl Sci. 2017 May;10(3):143-146. doi: 10.1111/cts.12456. Epub 2017 Mar 14.
10
Personalized Therapeutics and Pharmacogenomics: Integral to Personalized Health Care.
Pharm Res. 2017 Aug;34(8):1535-1538. doi: 10.1007/s11095-017-2170-y. Epub 2017 May 10.
引用本文的文献
1
PharmFreq: a comprehensive atlas of ethnogeographic allelic variation in clinically important pharmacogenes.
Nucleic Acids Res. 2025 Jan 6;53(D1):D1498-D1509. doi: 10.1093/nar/gkae1016.
2
Clinical and economic outcomes of a pharmacogenomics-enriched comprehensive medication management program in a self-insured employee population.
Pharmacogenomics J. 2024 Oct 2;24(5):30. doi: 10.1038/s41397-024-00350-1.
3
Receptor Pharmacogenomics: Deciphering Genetic Influence on Drug Response.
Int J Mol Sci. 2024 Aug 29;25(17):9371. doi: 10.3390/ijms25179371.
4
Pharmacogenomic Determinants of Adverse Drug Effects: A Systematic Review and Meta-analysis.
In Vivo. 2024 Sep-Oct;38(5):2098-2106. doi: 10.21873/invivo.13671.
5
Opioid use disorder risk alleles in self-reported assigned African American/Afro-Caribbean and European biogeographical genetic ancestry groups and in males and females.
Pharmacogenomics J. 2024 Aug 1;24(4):23. doi: 10.1038/s41397-024-00337-y.
6
Approaches and hurdles of implementing pharmacogenetic testing in the psychiatric clinic.
PCN Rep. 2022 Jun 22;1(2):e26. doi: 10.1002/pcn5.26. eCollection 2022 Jun.
7
Forging the path to precision medicine in Qatar: a public health perspective on pharmacogenomics initiatives.
Front Public Health. 2024 Mar 14;12:1364221. doi: 10.3389/fpubh.2024.1364221. eCollection 2024.
8
Challenges of pediatric pharmacotherapy: A narrative review of pharmacokinetics, pharmacodynamics, and pharmacogenetics.
Eur J Clin Pharmacol. 2024 Feb;80(2):203-221. doi: 10.1007/s00228-023-03598-x. Epub 2023 Dec 11.
9
External control arms: COVID-19 reveals the merits of using real world evidence in real-time for clinical and public health investigations.
Front Med (Lausanne). 2023 Jul 6;10:1198088. doi: 10.3389/fmed.2023.1198088. eCollection 2023.
10
Pharmacogenomics: current status and future perspectives.
Nat Rev Genet. 2023 Jun;24(6):350-362. doi: 10.1038/s41576-022-00572-8. Epub 2023 Jan 27.
本文引用的文献
1
When will clinical trials finally reflect diversity?
Nature. 2018 May;557(7704):157-159. doi: 10.1038/d41586-018-05049-5.
2
Pharmacogenomic substudies of randomized controlled trials: consideration of safety outcomes.
Ther Adv Drug Saf. 2014 Apr;5(2):62-6. doi: 10.1177/2042098613520030.
3
HLA diversity in the 1000 genomes dataset.
PLoS One. 2014 Jul 2;9(7):e97282. doi: 10.1371/journal.pone.0097282. eCollection 2014.
4
Promises and challenges of pharmacogenetics: an overview of study design, methodological and statistical issues.
JRSM Cardiovasc Dis. 2012 Apr 5;1(1):cvd.2012.012001. doi: 10.1258/cvd.2012.012001.
5
Pharmacogenetic tests: the need for a level playing field.
Nat Rev Drug Discov. 2013 Jan;12(1):3-4. doi: 10.1038/nrd3921.
Zotero 插件